Boston Advisors LLC increased its position in Horizon Pharma Inc. (NASDAQ:HZNP) by 47.3% during the second quarter, according to its most recent filing with the SEC. The fund owned 22,485 shares of the biopharmaceutical company’s stock after buying an additional 7,220 shares during the period. Boston Advisors LLC’s holdings in Horizon Pharma were worth $370,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Virginia Retirement System bought a new stake in Horizon Pharma during the first quarter worth approximately $282,000. Algert Global LLC boosted its stake in shares of Horizon Pharma by 57.3% in the first quarter. Algert Global LLC now owns 20,872 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 7,602 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of Horizon Pharma by 5,195.9% in the first quarter. Franklin Resources Inc. now owns 1,276,730 shares of the biopharmaceutical company’s stock worth $21,155,000 after buying an additional 1,252,622 shares during the last quarter. BlackRock Group LTD boosted its stake in shares of Horizon Pharma by 21.0% in the first quarter. BlackRock Group LTD now owns 100,919 shares of the biopharmaceutical company’s stock worth $1,672,000 after buying an additional 17,505 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its stake in shares of Horizon Pharma by 7.6% in the first quarter. BlackRock Fund Advisors now owns 2,937,687 shares of the biopharmaceutical company’s stock worth $48,677,000 after buying an additional 208,391 shares during the last quarter. 85.25% of the stock is currently owned by institutional investors.
Shares of Horizon Pharma Inc. (NASDAQ:HZNP) traded down 1.21% on Friday, reaching $18.73. 1,988,610 shares of the company traded hands. Horizon Pharma Inc. has a 1-year low of $12.86 and a 1-year high of $23.70. The stock has a 50-day moving average price of $19.14 and a 200 day moving average price of $17.80. The firm’s market capitalization is $3.01 billion.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.12. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%. The business had revenue of $257.40 million for the quarter, compared to the consensus estimate of $235.43 million. During the same period last year, the firm earned $0.39 earnings per share. The company’s quarterly revenue was up 48.9% on a year-over-year basis. Analysts anticipate that Horizon Pharma Inc. will post $2.15 EPS for the current fiscal year.
A number of equities research analysts have issued reports on HZNP shares. Vetr raised shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating and set a $21.00 target price on the stock in a report on Monday, June 13th. BMO Capital Markets started coverage on shares of Horizon Pharma in a report on Tuesday, June 28th. They set an “outperform” rating and a $29.00 target price on the stock. Stifel Nicolaus reissued a “buy” rating and set a $45.00 target price on shares of Horizon Pharma in a report on Wednesday, July 6th. Morgan Stanley raised shares of Horizon Pharma from an “underweight” rating to an “equal weight” rating and set a $24.00 target price on the stock in a report on Monday, July 11th. Finally, Zacks Investment Research raised shares of Horizon Pharma from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Monday, July 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $30.00.
In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of the stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total value of $58,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 2.10% of the stock is currently owned by company insiders.
Horizon Pharma Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma Inc. (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.